Wright Medical Group, Inc. (Wright) has received US Food and Drug Administration (FDA) approval to market its original CONSERVE Plus Total Hip Resurfacing System. This total surface arthroplasty system provides surgeons and their patients a bone-conserving alternative to traditional total hip replacement.
The approval permits Wright to market CONSERVE Plus in the original femoral and acetabular component configuration specified in its PreMarket Approval (PMA) application and enables the company to initiate efforts to introduce additional enhancements to the system which are currently only available outside of the United States. The Company intends to incorporate these innovative future product options into the CONSERVE Plus System’s femoral and acetabular component offerings via the PMA Supplement pathway.
The CONSERVE Plus system is designed to offer pain relief and restoration of function while retaining as much healthy bone as possible and preserving future surgery options, including a primary total hip replacement.
The approval follows a successful clinical trial involving more than 1,300 patients, including those enrolled under Continued Access protocols, providing patient data of CONSERVE Plus clinical data in postoperative periods of up to eight years in length. Wright will commence surgeon training in the first phase of its US introduction. The training is expected to begin immediately upon approval.
“Hip resurfacing represents a valuable alternative to younger, more active patients who desire a hip reconstruction that more anatomically mimics the natural hip,” commented Patrick Fisher, Sr. Director of Marketing for Wright’s hip franchise. “We have learned that this is an option for patients who meet the criteria for hip resurfacing, and these individuals tend to be very enthusiastic and outspoken about their positive results.”